Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: NRL005
MIFTS: 61

Neurilemmoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Neurilemmoma

About this section

MalaCards integrated aliases for Neurilemmoma:

Name: Neurilemmoma 11 19 58 43 14 71 75
Schwannoma 11 19 53 5 16 75
Benign Schwannoma 19 58 71
Peripheral Fibroblastoma 19 58
Neurilemoma 19 58
Psammomatous Schwannoma 11
Neurolemmoma 19
Schwannomas 14

Characteristics:


Prevelance:

Benign Schwannoma: 1-9/100000 (Europe) 58

Age Of Onset:

Benign Schwannoma: Adult,Elderly 58

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)
Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 11 DOID:3192
MeSH 43 D009442
NCIt 49 C3269
SNOMED-CT 68 985004
UMLS via Orphanet 72 C0027809 C0854906
Orphanet 58 ORPHA252164
UMLS 71 C0027809 C0854906
Sources

Summaries for Neurilemmoma

About this section

GARD: 19 A Schwannoma is a tumor of the peripheral nervous system or nerve root. A Schwannoma develops from cells called Schwann cells, a type of cell that wraps itself around peripheral nerves and provides protection and support. Schwannomas are almost always benign (not cancerous), but rarely, may become cancerous (a malignant Schwannoma). Symptoms of a Schwannoma may be vague and will vary depending on its location and size, but may include a lump or bump that can be seen or felt, pain, muscle weakness, tingling, numbness, hearing problems, and/or facial paralysis. Sometimes Schwannomas do not cause any symptoms. Schwannomas usually develop in otherwise healthy people for unknown reasons. In some cases, a Schwannoma is caused by a genetic disorder such as neurofibromatosis 2 (NF2), Schwannomatosis, or Carney complex. People with these genetic disorders usually have more than one Schwannoma. Schwannomas may be diagnosed using imaging studies. A biopsy may confirm the diagnosis.

MalaCards based summary: Neurilemmoma, also known as schwannoma, is related to peripheral nerve schwannoma and neurilemmoma of the fifth cranial nerve. An important gene associated with Neurilemmoma is SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1), and among its related pathways/superpathways are Signal Transduction and Malignant pleural mesothelioma. The drugs Lapatinib and Axitinib have been mentioned in the context of this disorder. Affiliated tissues include brain, breast and spinal cord, and related phenotypes are abnormal temporal bone morphology and vestibular schwannoma

Orphanet: 58 A rare benign peripheral nerve sheath tumor characterized by a usually encapsulated space-occupying lesion composed of differentiated neoplastic Schwann cells. It most commonly arises from peripheral nerves in the head and neck region and extensor aspects of the extremities, but also from spinal and cranial nerves, especially the vestibular nerve. The tumor may be asymptomatic or cause symptoms related to a mass effect. It grows slowly and only rarely undergoes malignant transformation.

Disease Ontology: 11 A neuroma that is characterized as a benign nerve sheath tumor that is composed of Schwann cells.

Wikipedia: 75 A schwannoma (or neurilemmoma) is a usually benign nerve sheath tumor composed of Schwann cells, which... more...
Sources

Related Diseases for Neurilemmoma

About this section

Diseases related to Neurilemmoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1312)
# Related Disease Score Top Affiliating Genes
1 peripheral nerve schwannoma 32.4 SMARCB1 NF2 NF1
2 neurilemmoma of the fifth cranial nerve 32.4 NF2 NF1 CD34
3 melanotic neurilemmoma 32.4 SOX10 SMARCB1 PRKAR1A NF2
4 schwannomatosis 1 32.3 SMARCB1 NF2
5 carney complex variant 32.2 PRKAR1A NF2 NF1
6 schwannoma of twelfth cranial nerve 32.1 SMARCB1 NF2 NF1
7 adult malignant schwannoma 32.1 SOX10 NF1 KIT CD34
8 intraneural perineurioma 32.0 SOX10 NF2 CD34
9 cellular schwannoma 31.9 SOX10 SMARCB1 NF2 NF1 KIT CD34
10 plexiform schwannoma 31.7 SOX10 SMARCB1 NF2 NF1 KIT ENO2
11 acoustic neuroma 31.7 SMARCB1 RDX NGFR NF2 NF1 MSN
12 malignant peripheral nerve sheath tumor 31.4 VIM SOX10 S100B S100A1 PDGFRA NGFR
13 hydrocephalus 31.3 SMARCB1 S100B NES GFAP ENO2
14 mesenchymal cell neoplasm 31.2 SMARCB1 PDGFRA NF1 KIT CD34
15 cerebellopontine angle tumor 31.1 SMARCB1 NF2
16 obstructive hydrocephalus 30.8 NF2 NF1 GFAP ENO2
17 epidural spinal canal neoplasm 30.8 NF2 NF1 CD34
18 myoblastoma 30.7 SOX10 ENO2
19 bap1 tumor predisposition syndrome 30.7 SMARCB1 PRKAR1A NF2 NF1 KIT
20 perineurioma 30.7 VIM S100B NF2 MUC1 KIT CD34
21 plexiform neurofibroma 30.7 SOX10 SMARCB1 S100B PDGFRA NF2 NF1
22 olfactory groove meningioma 30.7 SMARCB1 NF2
23 syringomyelia 30.7 NF1 NES GFAP
24 cellular ependymoma 30.7 VIM S100B NF2 NES MUC1 GFAP
25 spinal meningioma 30.6 SMARCB1 NF2 NF1
26 connective tissue benign neoplasm 30.6 SOX10 NF1 KIT ENO2 CD34
27 leiomyoma 30.6 VIM S100A1 KIT CD34 ACTC1
28 neurofibromatosis 30.6 SMARCB1 RDX PDGFRA NF2 NF1 MSN
29 mediastinal cancer 30.6 KIT ENO2 CD34
30 neuroblastoma 30.6 NGFR NF1 NES KIT GFAP ENO2
31 sarcoma 30.6 VIM SMARCB1 S100B S100A1 PDGFRA MUC1
32 granular cell tumor 30.6 VIM S100B S100A1 GFAP ENO2
33 myoma 30.6 KIT ENO2 CD34 ACTC1
34 angiosarcoma 30.5 VIM PDGFRA MUC1 KIT CD34 ACTC1
35 ganglioneuroma 30.5 S100B GFAP ENO2
36 inherited cancer-predisposing syndrome 30.5 SMARCB1 PRKAR1A NF2 NF1 KIT
37 orbital cancer 30.4 NF2 NF1 ENO2 CD34
38 epithelioid malignant peripheral nerve sheath tumor 30.4 SOX10 SMARCB1 NF1 ENO2 CD34
39 pheochromocytoma 30.4 VIM S100B NGFR NF1 KIT ENO2
40 lipomatosis, multiple 30.4 S100A1 NF1 KIT CD34
41 fibroma 30.4 VIM S100A1 NF1 CD34 ACTC1
42 amelanotic melanoma 30.4 SOX10 S100B KIT ENO2
43 adrenal carcinoma 30.4 VIM PRKAR1A NF1 ENO2
44 full schwannomatosis 30.4 SMARCB1 NF2
45 gastrointestinal stromal tumor 30.3 VIM SOX10 S100B S100A1 PDGFRA NF2
46 fibrous histiocytoma 30.3 VIM SOX10 S100B CD34 ACTC1
47 fibrosarcoma 30.3 VIM PDGFRA KIT ACTC1
48 intracranial meningioma 30.3 SMARCB1 NF2 NF1
49 glioblastoma 30.3 SOX10 PDGFRA NF2 NF1 NES KIT
50 atypical teratoid rhabdoid tumor 30.3 SMARCB1 NF2 NF1 GFAP

Graphical network of the top 20 diseases related to Neurilemmoma:



Diseases related to Neurilemmoma
Sources

Symptoms & Phenotypes for Neurilemmoma

About this section

Human phenotypes related to Neurilemmoma:

58 30 (show all 26)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormal temporal bone morphology 58 30 Hallmark (90%) Very frequent (99-80%)
 HP:0009911
2 vestibular schwannoma 58 30 Hallmark (90%) Very frequent (99-80%)
 HP:0009588
3 peripheral schwannoma 58 30 Hallmark (90%) Very frequent (99-80%)
 HP:0009593
4 abnormality of peripheral nervous system electrophysiology 58 30 Hallmark (90%) Very frequent (99-80%)
 HP:0030177
5 scleral schwannoma 58 30 Hallmark (90%) Very frequent (99-80%)
 HP:0100011
6 facial palsy 58 30 Frequent (33%) Frequent (79-30%)
 HP:0010628
7 hearing abnormality 58 30 Frequent (33%) Frequent (79-30%)
 HP:0000364
8 vertigo 58 30 Frequent (33%) Frequent (79-30%)
 HP:0002321
9 allodynia 58 30 Frequent (33%) Frequent (79-30%)
 HP:0012533
10 abnormality of the liver 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0001392
11 nasal polyposis 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0100582
12 abnormality of the adrenal glands 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0000834
13 intestinal polyposis 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0200008
14 abnormality of the larynx 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0001600
15 abnormality of fibula morphology 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0002991
16 acute episodes of neuropathic symptoms 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0003489
17 abnormal parotid gland morphology 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0000197
18 abnormality of the breast 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0000769
19 abnormal esophagus morphology 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0002031
20 abnormality of the twelfth cranial nerve 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0010826
21 morphological central nervous system abnormality 30 Occasional (7.5%) HP:0002011
22 abnormal cranial nerve morphology 58 Very frequent (99-80%)
23 morphological abnormality of the central nervous system 58 Occasional (29-5%)
24 pain 58 Occasional (29-5%)
25 schwannoma 58 Very frequent (99-80%)
26 neurofibrosarcoma 58 Excluded (0%)

GenomeRNAi Phenotypes related to Neurilemmoma according to GeneCards Suite gene sharing:

25 (show all 14)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.18 ACTC1 CD34 ENO2 EZR GFAP KIT
2 no effect GR00402-S-2 10.18 ACTC1 CD34 EZR KIT MSN MUC1
3 Decreased viability GR00173-A 10 PDGFRA
4 Decreased viability GR00221-A-1 10 KIT NF1 PDGFRA PRKAR1A SMARCB1
5 Decreased viability GR00221-A-2 10 NF1 PRKAR1A SMARCB1
6 Decreased viability GR00221-A-3 10 PDGFRA PRKAR1A SMARCB1
7 Decreased viability GR00221-A-4 10 NF1 PDGFRA PRKAR1A
8 Decreased viability GR00249-S 10 NF1 PDGFRA SMARCB1
9 Decreased viability GR00301-A 10 KIT
10 Decreased viability GR00381-A-1 10 SMARCB1
11 Decreased viability GR00386-A-1 10 NF1
12 Decreased viability GR00402-S-2 10 PDGFRA
13 Increased cell migration GR00055-A-1 9.16 NF1
14 Increased cell migration GR00055-A-3 9.16 NF1

MGI Mouse Phenotypes related to Neurilemmoma:

45 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.48 ACTC1 CD34 GFAP KIT MSN MUC1
2 normal MP:0002873 10.38 ACTC1 GFAP KIT MSN MUC1 NF1
3 nervous system MP:0003631 10.37 ACTC1 ENO2 GFAP KIT NES NF1
4 growth/size/body region MP:0005378 10.36 ACTC1 ENO2 EZR GFAP KIT MSN
5 cellular MP:0005384 10.31 ACTC1 CD34 ENO2 GFAP KIT MSN
6 behavior/neurological MP:0005386 10.3 ACTC1 ENO2 GFAP KIT MSN NES
7 muscle MP:0005369 10.25 ACTC1 GFAP KIT NF1 NGFR PDGFRA
8 neoplasm MP:0002006 10.23 CD34 KIT MUC1 NF1 NF2 PDGFRA
9 digestive/alimentary MP:0005381 10.22 EZR GFAP KIT MUC1 NF1 NF2
10 embryo MP:0005380 10.15 KIT NES NF1 NF2 PDGFRA PRKAR1A
11 liver/biliary system MP:0005370 10.14 KIT MUC1 NF1 NF2 NGFR PRKAR1A
12 cardiovascular system MP:0005385 10.14 ACTC1 GFAP KIT MSN NF1 NGFR
13 immune system MP:0005387 10.1 CD34 EZR GFAP KIT MSN NF1
14 pigmentation MP:0001186 10.06 KIT NF1 NF2 PDGFRA PRKAR1A SOX10
15 craniofacial MP:0005382 10 ENO2 KIT NF1 NF2 NGFR PDGFRA
16 respiratory system MP:0005388 10 ENO2 KIT MSN NF1 NF2 NGFR
17 vision/eye MP:0005391 9.9 EZR GFAP KIT MSN MUC1 NF1
18 mortality/aging MP:0010768 9.8 ACTC1 EZR GFAP KIT NES NF1
19 integument MP:0010771 9.36 CD34 KIT MUC1 NF1 NF2 NGFR
Sources

Drugs & Therapeutics for Neurilemmoma

About this section

Drugs for Neurilemmoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 64)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908
2
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
3
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
4
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
5
Lidocaine Approved, Vet_approved Phase 1, Phase 2 137-58-6 3676
6
Doxycycline Approved, Investigational, Vet_approved Phase 1, Phase 2 564-25-0 54671203
7
Acetylsalicylic acid Approved, Vet_approved Phase 2 50-78-2 2244
8
Nimodipine Approved, Investigational Phase 2 66085-59-4 4497
9
Crizotinib Approved, Investigational Phase 2 877399-52-5 11626560
10
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
11
Losartan Approved Phase 2 114798-26-4 3961
12
Angiotensin II Approved, Investigational Phase 2 68521-88-0, 11128-99-7, 4474-91-3 172198
13
Tanezumab Investigational Phase 2 880266-57-9
14 Angiogenesis Inhibitors Phase 2
15 Endostatins Phase 2
16 Immunoglobulins, Intravenous Phase 2
17 Antibodies, Monoclonal Phase 2
18 Antineoplastic Agents, Immunological Phase 2
19 Endothelial Growth Factors Phase 2
20 Hormones Phase 2
21 Anti-Inflammatory Agents Phase 2
22 Antiprotozoal Agents Phase 1, Phase 2
23 Antiparasitic Agents Phase 1, Phase 2
24 Antimalarials Phase 1, Phase 2
25 Antirheumatic Agents Phase 2
26 Fibrinolytic Agents Phase 2
27 Antipyretics Phase 2
28 Cyclooxygenase Inhibitors Phase 2
29 Platelet Aggregation Inhibitors Phase 2
30 Anti-Inflammatory Agents, Non-Steroidal Phase 2
31 Analgesics, Non-Narcotic Phase 2
32 Vasodilator Agents Phase 2
33 Calcium, Dietary Phase 2
34 calcium channel blockers Phase 2
35 Pharmaceutical Solutions Phase 2
36 Gelatin Sponge, Absorbable Phase 2
37 Immunosuppressive Agents Phase 2
38 Immunologic Factors Phase 2
39 Protein Kinase Inhibitors Phase 2
40 Analgesics Phase 2
41 Immunoglobulins Phase 2
42 Antibodies Phase 2
43 Mitogens Phase 2
44 Antihypertensive Agents Phase 2
45 Anti-Arrhythmia Agents Phase 2
46
Angiotensinogen Phase 2 16133225
47 Angiotensin Receptor Antagonists Phase 2
48 Angiotensin II Type 1 Receptor Blockers Phase 2
49 Giapreza Phase 2
50
Calcium Nutraceutical Phase 2 7440-70-2 271

Interventional clinical trials:

(show top 50) (show all 79)
# Name Status NCT ID Phase Drugs
1 Gentamicin Treatment Prior to Vestibular Schwannoma Surgery in Patients With Definite Remaining Vestibular Function Withdrawn NCT02379754 Phase 4 Gentamicins
2 Gentamicin Treatment Prior to Vestibular Schwannoma Surgery in Patients With no Measurable Remaining Vestibular Function Withdrawn NCT02415257 Phase 4 Gentamicin
3 Randomized Comparison of Steretotactic Radiosurgery and Hypofractionated Steretotactic Radiotherapy in the Treatment of Vestibular Schwannoma Unknown status NCT01449604 Phase 3
4 Recombinant Human Endostatin Injection Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors by Continuous Intravenous Pumping Completed NCT02104323 Phase 2 Endostatin
5 Phase II Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Completed NCT02129647 Phase 2 Axitinib
6 Phase II Study of Lapatinib in Children and Adults With Neurofibromatosis Type 2(NF2) and NF2-related Tumors Completed NCT00973739 Phase 2 Lapatinib
7 Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas Completed NCT01125046 Phase 2
8 Phase 2 Study of Bevacizumab in Children and Adults With Neurofibromatosis Type 2 and Symptomatic Vestibular Schwannoma Completed NCT01207687 Phase 2
9 Open-label, Phase 2 Study of Bevacizumab in Children and Young Adults With Neurofibromatosis 2 and Progressive Vestibular Schwannomas That Are Poor Candidates for Standard Treatment With Surgery or Radiation Completed NCT01767792 Phase 2 Bevacizumab
10 A Single Arm, Single Center, Phase II Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis Type 2 - Related Vestibular Schwannoma Completed NCT01490476 Phase 2 RAD001
11 Icotinib Hydrochloride Tablets Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT02934256 Phase 2 Icotinib
12 Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2) Recruiting NCT04374305 Phase 2 Brigatinib;Neratinib
13 Doxycycline Injection of Cutaneous Schwannoma in Neurofibromatosis Type 2 Recruiting NCT05521048 Phase 1, Phase 2 Doxycycline Injection [Doxy]
14 Phase 2 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2 Selumetinib
15 Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560 Recruiting NCT04351373 Phase 2 intravenous fluorescein sodium
16 Prospective, Randomized, Placebo-Controlled Phase II Trial of Aspirin for Vestibular Schwannomas Recruiting NCT03079999 Phase 2 Aspirin;Placebo
17 Intraoperative Application of Nimodipine to the Facial and Cochlear Nerves During Vestibular Schwannoma Resection to Avoid Spasm-related Postoperative Facial Paralysis and Deafness - a Prospective Randomized Pilot Study Recruiting NCT04801953 Phase 2 NiMODipine Injectable Solution
18 Open-label, Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Active, not recruiting NCT04283669 Phase 2 Crizotinib
19 A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Analgesic Efficacy and Safety of the Subcutaneous Administration of the Anti-NGF Antibody Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis Active, not recruiting NCT04163419 Phase 2 Tanezumab;Placebo
20 Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma Active, not recruiting NCT01199978 Phase 2 Losartan
21 A Single Arm, Monocenter Phase II Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis Type 2 - Related Vestibular Schwannoma Active, not recruiting NCT01345136 Phase 2 RAD001, everolimus
22 Phase II Study of Antineoplastons A19 and AS2-1 in Patients With Neurofibroma and Schwannoma Terminated NCT02988726 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
23 A Phase II Study of Nilotinib in Growing Vestibular Schwannomas Terminated NCT01201538 Phase 2 Nilotinib
24 Triamcinolone Acetonide Levels in Cochlear Perilymph, Lateral Canal and CSF in Patients With Vestibular Schwannomas Completed NCT04658836 Phase 1 Triamcinolone Acetonide 40mg/mL
25 Phase 1 Trial of RO4929097 in Combination With Standard Radiotherapy and Temozolomide for Newly Diagnosed Malignant Glioma: A Pharmacokinetic and Pharmacodynamic Study Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
26 Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET Recruiting NCT03542773 Phase 1 18F-DCFPyL Injection
27 Phase I Trial of Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma (Acoustic Neuroma) Suspended NCT01083966 Phase 1 Bevacizumab (Avastin)
28 Novel Multimodality Imaging Techniques for Neurosurgical Planning and Stereotactic Navigation in Lateral Skull Base Surgery: a Feasibility Study Unknown status NCT04128345
29 The Impact of Vestibular Rehabilitation on the Longitudinal Recovery of Laboratory, Clinical, and Community-Based Measures of Head and Trunk Control in People With Acquired Vestibulopathy Unknown status NCT04594057
30 Assessment of the Preoperative Vestibular Rehabilitation Effectiveness on Balance Control Compensation After Vestibular Schwannoma Surgery Unknown status NCT02275325
31 Response Prediction After Gamma Knife Surgery (GKS) in Patients With Vestibular Schwannoma Using Dynamic Contrast-Enhanced (DCE) MR Imaging Unknown status NCT03097822
32 Evolution of Cochleovestibular Schwannomas in the Internal Auditory Canal by Volume Measering With aTeslas MRI 3 Unknown status NCT04417868
33 Saccular Dilatation, Endolymphatic Hydrops and Vestibular Schwannoma : is Vertigo Really Correlated to the Tumor ? A Retrospective Study Based on FIESTA-C Sequence Using a 3 Tesla MRI Unknown status NCT03593577
34 Consequence of Unilateral Vestibular Loss on Visual Abilities Unknown status NCT03581331
35 INTEREST OF INTRAVENOUS INJECTION OF GADOLINIUM IN EXPLORATION INTRA-LABYRINTHINE SCHWANNOMA IN MRI 3 TESLAS Unknown status NCT03580850
36 NF2 Natural History Consortium Unknown status NCT00004483
37 Scleral Hydrops and Intralabyrinthine Schwannoma Unknown status NCT03581396
38 Protocol for Evaluating a Planning Algorithm for Gamma Knife Radiosurgery Unknown status NCT03520829
39 Evaluation of the Influence of Psychological Factors on Balance Control Compensation After Vestibular Schwannoma Surgery Unknown status NCT01743248
40 Assessment of Volumetric Growth Rates of Spinal Intradural Extramedullary Schwannoma: A Longitudinal Study of Natural History Completed NCT01951365
41 Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas Completed NCT01880749 Early Phase 1 RAD001
42 Vestibular Evaluation Before and After Treatment of Vestibular Schwannoma. Comparison of Gamma Knife Radiosurgery and Microsurgical Resection Completed NCT03670589
43 Exploration and Estimation of Intratumoral Concentration and Activity of Lapatinib in Vivo in Vestibular Schwannomas Completed NCT00863122 Early Phase 1 lapatinib
44 Vestibular Schwannoma - Radiosurgery or Expectation Completed NCT02249572
45 Vertigo Perception and Quality of Life in Patients After Surgical Treatment of Vestibular Schwannoma With Pretreatment Prehabituation by Chemical Vestibular Ablation Completed NCT02963896 gentamicin
46 Recovery of Visual Acuity in Vestibular Deficits Completed NCT00411216
47 Hippocampal Radiation Exposure and Memory: A Pilot Study Completed NCT00603694
48 Whole Exome Sequencing (WES) of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data Completed NCT03210285
49 Vegetative Monitoring During Brainstem-associated Surgery Completed NCT03666507
50 Alternatives to The Surgical Approach for Giant Spinal Schwannomas: A Clinic Trial Completed NCT02494622

Search NIH Clinical Center for Neurilemmoma

Cochrane evidence based reviews: neurilemmoma

Sources

Genetic Tests for Neurilemmoma

About this section
Sources

Anatomical Context for Neurilemmoma

About this section

Organs/tissues related to Neurilemmoma:

MalaCards : Brain, Breast, Spinal Cord, Bone, Liver, Small Intestine, Tongue
Sources

Publications for Neurilemmoma

About this section

Articles related to Neurilemmoma:

(show top 50) (show all 16840)
# Title Authors PMID Year
1
Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis. 53 62
20195187 2010
2
Novel immunohistochemical markers in the diagnosis of nonglial tumors of nervous system. 53 62
20179436 2010
3
Palisaded encapsulated ("solitary circumscribed") neuroma of the oral cavity: a review of 55 cases. 53 62
20237984 2010
4
Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. 53 62
20178741 2010
5
Best practices in diagnostic immunohistochemistry: spindle cell neoplasms of the gastrointestinal tract. 53 62
19722741 2009
6
NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. 53 62
19451225 2009
7
Charcot-Marie-Tooth 1A concurrent with schwannomas of the spinal cord and median nerve. 53 62
19654968 2009
8
Gastric schwannoma with adjacent external progression harbored aberrant NF2 gene. 53 62
19691769 2009
9
Use of mouse models to understand the molecular basis of tissue-specific tumorigenesis in the Carney complex. 53 62
19522826 2009
10
PAK kinase regulates Rac GTPase and is a potential target in human schwannomas. 53 62
19409384 2009
11
Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate). 53 62
19509233 2009
12
The phosphorylation status of merlin in sporadic vestibular Schwannomas. 53 62
19142715 2009
13
Actin expression in neural crest cell-derived tumors including schwannomas, malignant peripheral nerve sheath tumors, neurofibromas and melanocytic tumors. 53 62
19154261 2009
14
Nestin expression correlates with nerve and retroperitoneal tissue invasion in pancreatic cancer. 53 62
18799194 2009
15
Meningiomas and schwannomas: molecular subgroup classification found by expression arrays. 53 62
19148485 2009
16
Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas. 53 62
19029950 2009
17
Altered adhesive structures and their relation to RhoGTPase activation in merlin-deficient Schwannoma. 53 62
18445079 2009
18
Expanded endoscopic endonasal resection of an olfactory schwannoma. 53 62
18831660 2008
19
Sox10: a pan-schwannian and melanocytic marker. 53 62
18636017 2008
20
Identification of direct regulatory targets of the transcription factor Sox10 based on function and conservation. 53 62
18786246 2008
21
Benign schwannoma of the liver: a case report. 53 62
18756066 2008
22
Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma. 53 62
18593924 2008
23
Perirenal schwannoma: a case report. 53 62
18518995 2008
24
Diagnostic implications of podoplanin expression in peripheral nerve sheath neoplasms. 53 62
18480004 2008
25
Impaired intercellular adhesion and immature adherens junctions in merlin-deficient human primary schwannoma cells. 53 62
18240308 2008
26
Targeted deletion of Prkar1a reveals a role for protein kinase A in mesenchymal-to-epithelial transition. 53 62
18413734 2008
27
Magic but treatable? Tumours due to loss of merlin. 53 62
17940085 2008
28
Evidence of a four-hit mechanism involving SMARCB1 and NF2 in schwannomatosis-associated schwannomas. 53 62
18072270 2008
29
Pituitary-specific knockout of the Carney complex gene Prkar1a leads to pituitary tumorigenesis. 53 62
17975024 2008
30
Point mutation in the NF2 gene of HEI-193 human schwannoma cells results in the expression of a merlin isoform with attenuated growth suppressive activity. 53 62
17868749 2008
31
Genesis and biology of vestibular schwannomas. 53 62
18810196 2008
32
Schwannoma of the lip: case report and review of the literature. 53 62
18758646 2008
33
Multiple schwannomas: report of two cases. 53 62
17216226 2007
34
Role of NF2 haploinsufficiency in NF2-associated polyneuropathy. 53 62
17655741 2007
35
Male infertility as a component of Carney complex. 53 62
17714219 2007
36
Evaluation of NF2 gene deletion in sporadic schwannomas, meningiomas, and ependymomas by chromogenic in situ hybridization. 53 62
17509660 2007
37
Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB. 53 62
17558420 2007
38
The tumor suppressor merlin interacts with microtubules and modulates Schwann cell microtubule cytoskeleton. 53 62
17566081 2007
39
Actin-rich protrusions and nonlocalized GTPase activation in Merlin-deficient schwannomas. 53 62
17620986 2007
40
Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta. 53 62
17304235 2007
41
Comparative study using rabbit-derived polyclonal, mouse-derived monoclonal, and rabbit-derived monoclonal antibodies for KIT immunostaining in GIST and other tumors. 53 62
17316415 2007
42
Phosphorylation of the NF2 tumor suppressor in Schwann cells is mediated by Cdc42-Pak and requires paxillin binding. 53 62
17175165 2007
43
Nestin expression as a new marker in malignant peripheral nerve sheath tumors. 53 62
17300669 2007
44
Intracranial angiosarcoma arising from a schwannoma. 53 62
16995966 2007
45
Esophageal schwannoma: report of a case. 53 62
17522770 2007
46
Down-regulation of Sox10 with specific small interfering RNA promotes transdifferentiation of Schwannoma cells into myofibroblasts. 53 62
17177851 2006
47
Melanotic nonpsammomatous trigeminal schwannoma as the first manifestation of Carney complex: case report. 53 62
17277668 2006
48
Differential gene expression between human schwannoma and control Schwann cells. 53 62
17083475 2006
49
Primary intraosseous melanotic schwannoma of the fibula associated with the Carney complex. 53 62
16930334 2006
50
A functional association between merlin and HEI10, a cell cycle regulator. 53 62
16532029 2006
Sources

Variations for Neurilemmoma

About this section

ClinVar genetic disease variations for Neurilemmoma:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SMARCB1 NM_003073.5(SMARCB1):c.*82C>T SNV Pathogenic
 239481 rs878854600 GRCh37: 22:24176449-24176449
GRCh38: 22:23834262-23834262

Copy number variations for Neurilemmoma from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 163102 22 24129150 24176704 Deletion or amplification SMARCB1 Schwannoma
Sources

Expression for Neurilemmoma

About this section
Search GEO for disease gene expression data for Neurilemmoma.
Sources

Pathways for Neurilemmoma

About this section

Pathways related to Neurilemmoma according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Signal Transduction 66
13.52 ACTC1 GFAP KIT NF1 NF2 NGFR
2
Malignant pleural mesothelioma 74
12.52 PDGFRA NGFR NF2 KIT ACTC1
3
Neuroscience 3
12.23 S100B PRKAR1A NGFR NF2 NF1 GFAP
4
Ras signaling 74
12.06 PDGFRA NGFR NF1 KIT
5
Cytoskeletal Signaling 3
11.99 VIM RDX NF2 MUC1 MSN EZR
6
Regulation of actin cytoskeleton 74
11.94 RDX PDGFRA MSN EZR
7
Mesenchymal Stem Cells and Lineage-specific Markers 65
11.69 NGFR KIT CD34
8
Hippo-Merlin signaling dysregulation 74
Show member pathways
 11.63 PDGFRA NGFR NF2 KIT
9
Cardiac progenitor differentiation 74
11.38 PDGFRA KIT ACTC1
10
Cytoskeleton remodeling_RalA regulation pathway 22
11.37 RDX MSN EZR ACTC1
11
Melanocyte Development and Pigmentation 64
11.22 SOX10 PRKAR1A KIT
12
Neural Stem Cells and Lineage-specific Markers 65
11 VIM SOX10 S100B PDGFRA NES GFAP
13
G-protein signaling_Rap2B regulation pathway 22
10.7 VIM RDX PDGFRA MSN KIT GFAP
14
PtdIns(4,5)P2 in cytokinesis pathway 74
10.54 RDX MSN EZR
Sources

GO Terms for Neurilemmoma

About this section

Cellular components related to Neurilemmoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10.36 ACTC1 CD34 ENO2 EZR GFAP KIT
2 apical part of cell GO:0045177 9.97 RDX NF2 MSN EZR
3 cell projection GO:0042995 9.96 EZR GFAP MSN NF2 NGFR PDGFRA
4 microvillus GO:0005902 9.92 RDX PDGFRA MSN EZR
5 filopodium GO:0030175 9.61 RDX NF2 MSN EZR ACTC1
6 cell periphery GO:0071944 9.23 RDX NF2 MSN EZR CD34

Biological processes related to Neurilemmoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 regulation of cell shape GO:0008360 10.13 RDX MSN KIT EZR
2 stem cell proliferation GO:0072089 10.01 NF1 NES CD34
3 positive regulation of gene expression GO:0010628 10 ACTC1 CD34 EZR KIT MSN RDX
4 establishment of endothelial barrier GO:0061028 9.88 RDX MSN EZR
5 regulation of cell size GO:0008361 9.85 RDX MSN EZR
6 positive regulation of protein localization to early endosome GO:1902966 9.85 EZR MSN RDX
7 membrane to membrane docking GO:0022614 9.81 MSN EZR
8 mast cell proliferation GO:0070662 9.8 KIT NF1
9 positive regulation of early endosome to late endosome transport GO:2000643 9.8 RDX MSN EZR
10 positive regulation of histone H4 acetylation GO:0090240 9.78 MUC1 SMARCB1
11 negative regulation of Schwann cell proliferation GO:0010626 9.73 SOX10 NF2 NF1
12 intermediate filament-based process GO:0045103 9.43 VIM GFAP
13 regulation of organelle assembly GO:1902115 9.43 RDX MSN EZR
14 Schwann cell proliferation GO:0014010 9.1 NF2 NF1 GFAP

Molecular functions related to Neurilemmoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoskeletal protein binding GO:0008092 9.26 RDX NF2 MSN EZR
2 S100 protein binding GO:0044548 9.1 S100B S100A1 EZR
Sources

Sources for Neurilemmoma

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....